Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Prevention of Rhesus (D) alloimmunization in pregnancy

Kenneth J Moise Jr, MD
Section Editors
Charles J Lockwood, MD, MHCM
Arthur J Silvergleid, MD
Deputy Editor
Vanessa A Barss, MD, FACOG


Rhesus (Rh) D-negative pregnant women who are exposed to fetal D-positive red cells are at risk for developing anti-D antibodies. Widespread use of anti-D immunoglobulin (Rho(D) immune globulin) has dramatically reduced, but not eliminated, D alloimmunization.

Use of anti-D immunoglobulin for prevention of D alloimmunization will be discussed here. Related topics (a discussion of the Rhesus system, diagnosis and management of Rhesus alloimmunization in pregnancy, in utero transfusion, and neonatal issues) are reviewed in detail separately:

(See "Overview of Rhesus D alloimmunization in pregnancy".)

(See "Management of pregnancy complicated by Rhesus (D) alloimmunization".)

(See "Intrauterine fetal transfusion of red cells".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Aug 28, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Stasi R. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Curr Opin Mol Ther 2010; 12:734.
  2. Robak T, Windyga J, Trelinski J, et al. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood 2012; 120:3670.
  3. Witter FR, Shirey RS, Nicol SL, Ness PM. Postinjection kinetics of antepartum Rh immune globulin. Am J Obstet Gynecol 1990; 163:784.
  4. Andres RL, Branch DW, Scott JR. Elevated anti-D titer after the administration of Rh immune globulin. A case report. J Reprod Med 1989; 34:318.
  5. Kennedy MS, McNanie J, Waheed A. Detection of anti-D following antepartum injections of Rh immune globulin. Immunohematology 1998; 14:138.
  6. Lee D, Contreras M, Robson SC, et al. Recommendations for the use of anti-D immunoglobulin for Rh prophylaxis. British Blood Transfusion Society and the Royal College of Obstetricians and Gynaecologists. Transfus Med 1999; 9:93.
  7. Maayan-Metzger A, Schwartz T, Sulkes J, Merlob P. Maternal anti-D prophylaxis during pregnancy does not cause neonatal haemolysis. Arch Dis Child Fetal Neonatal Ed 2001; 84:F60.
  8. Kumpel BM. On the immunologic basis of Rh immune globulin (anti-D) prophylaxis. Transfusion 2006; 46:1652.
  9. Kumpel BM. On the mechanism of tolerance to the Rh D antigen mediated by passive anti-D (Rh D prophylaxis). Immunol Lett 2002; 82:67.
  10. Centers for Disease Control (CDC). Lack of transmission of human immunodeficiency virus through Rho(D) immune globulin (human). MMWR Morb Mortal Wkly Rep 1987; 36:728.
  11. Moise KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol 2002; 100:600.
  12. Okwundu CI, Afolabi BB. Intramuscular versus intravenous anti-D for preventing Rhesus alloimmunization during pregnancy. Cochrane Database Syst Rev 2013; :CD007885.
  13. Yap PL. Viral transmission by blood products: a perspective of events covered by the recent tribunal of enquiry into the Irish Blood Transfusion Board. Ir Med J 1997; 90:84, 86, 88.
  14. Wiese M, Berr F, Lafrenz M, et al. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. Hepatology 2000; 32:91.
  15. www.fda.gov/medwatch/safety/2006/safety06.htm#WinRho (Accessed on January 09, 2006).
  16. Jones ML, Wray J, Wight J, et al. A review of the clinical effectiveness of routine antenatal anti-D prophylaxis for rhesus-negative women who are pregnant. BJOG 2004; 111:892.
  17. Urbaniak SJ. The scientific basis of antenatal prophylaxis. Br J Obstet Gynaecol 1998; 105 Suppl 18:11.
  18. Bowman JM. Controversies in Rh prophylaxis. Who needs Rh immune globulin and when should it be given? Am J Obstet Gynecol 1985; 151:289.
  19. Bowman JM. The prevention of Rh immunization. Transfus Med Rev 1988; 2:129.
  20. Koelewijn JM, de Haas M, Vrijkotte TG, et al. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. Transfusion 2008; 48:1721.
  21. Huchet J, Dallemagne S, Huchet C, et al. [Ante-partum administration of preventive treatment of Rh-D immunization in rhesus-negative women. Parallel evaluation of transplacental passage of fetal blood cells. Results of a multicenter study carried out in the Paris region]. J Gynecol Obstet Biol Reprod (Paris) 1987; 16:101.
  22. Crowther C, Middleton P. Anti-D administration after childbirth for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev 2000; :CD000021.
  23. McBain RD, Crowther CA, Middleton P. Anti-D administration in pregnancy for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev 2015; :CD000020.
  24. de Silva M, Contreras M, Mollison PL. Failure of passively administered anti-Rh to prevent secondary Rh responses. Vox Sang 1985; 48:178.
  25. Bowman JM, Pollock JM. Reversal of Rh alloimmunization. Fact or fancy? Vox Sang 1984; 47:209.
  26. Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 181: Prevention of Rh D Alloimmunization. Obstet Gynecol 2017; 130:e57.
  27. United States Preventative Services Task Force. Rh(D) incompatibility: Screening. https://www.uspreventativeserice task force.org/Page/Document/RecommendationsStatementFinal/rh-d-incompatiobility-screening (Accessed on August 09, 2017).
  28. Fung Kee Fung K, Eason E, Crane J, et al. Prevention of Rh alloimmunization. J Obstet Gynaecol Can 2003; 25:765.
  29. Queenan JT. Rh immunoprophylaxis and fetal RHD genotyping: where are we going? Obstet Gynecol 2012; 120:219.
  30. Kent J, Farrell AM, Soothill P. Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice. BMC Pregnancy Childbirth 2014; 14:87.
  31. Rouillac-Le Sciellour C, Puillandre P, Gillot R, et al. Large-scale pre-diagnosis study of fetal RHD genotyping by PCR on plasma DNA from RhD-negative pregnant women. Mol Diagn 2004; 8:23.
  32. Finning K, Martin P, Summers J, et al. Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ 2008; 336:816.
  33. Müller SP, Bartels I, Stein W, et al. The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible. Transfusion 2008; 48:2292.
  34. Van der Schoot CE, Soussan AA, Koelewijn J, et al. Non-invasive antenatal RHD typing. Transfus Clin Biol 2006; 13:53.
  35. Clausen FB, Steffensen R, Christiansen M, et al. Routine noninvasive prenatal screening for fetal RHD in plasma of RhD-negative pregnant women-2 years of screening experience from Denmark. Prenat Diagn 2014; 34:1000.
  36. Wikman AT, Tiblad E, Karlsson A, et al. Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy. Obstet Gynecol 2012; 120:227.
  37. Chitty LS, Finning K, Wade A, et al. Diagnostic accuracy of routine antenatal determination of fetal RHD status across gestation: population based cohort study. BMJ 2014; 349:g5243.
  38. Mackie FL, Hemming K, Allen S, et al. The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis. BJOG 2017; 124:32.
  39. National Institute for Health and Care Excellence. High-throughput non-invasive prenatal testing for fetal RHD genotype 1: Recommendations. https://www.nice.org.uk/guidance/dg25/chapter/1-Recommendations (Accessed on August 09, 2017).
  40. de Haas M, Thurik FF, van der Ploeg CP, et al. Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands. BMJ 2016; 355:i5789.
  41. National Institute for Clinical Excellence. Guidance on the use of routine anti-D prophylaxis for RhD-negative women. Guideline #41. http://www.nice.org.uk (Accessed on March 01, 2016).
  42. Bowman JM, Pollock JM. Failures of intravenous Rh immune globulin prophylaxis: an analysis of the reasons for such failures. Transfus Med Rev 1987; 1:101.
  43. Koelewijn JM, de Haas M, Vrijkotte TG, et al. Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis. BJOG 2009; 116:1307.
  44. Royal College of Obstetricians and Gynaecologists. Green top guidelines. Anti-D immunoglobulin for Rh prophylaxis. RCOG; London, 2002.
  45. National Institute for Clinical Excellence. Guidelines. Pregnancy — routine anti-D prophylaxis for rhesus negative women (no 41). NICE; London, 2002.
  46. Fedrick J, Adelstein P. Factors associated with low birth weight of infants delivered at term. Br J Obstet Gynaecol 1978; 85:1.
  47. Karanth L, Jaafar SH, Kanagasabai S, et al. Anti-D administration after spontaneous miscarriage for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev 2013; :CD009617.
  48. Bowman J. Thirty-five years of Rh prophylaxis. Transfusion 2003; 43:1661.
  49. Meleti D, De Oliveira LG, Araujo Júnior E, et al. Evaluation of passage of fetal erythrocytes into maternal circulation after invasive obstetric procedures. J Obstet Gynaecol Res 2013; 39:1374.
  50. Lipitz S, Achiron R, Horoshovski D, et al. Fetomaternal haemorrhage discovered after trauma and treated by fetal intravascular transfusion. Eur J Obstet Gynecol Reprod Biol 1997; 71:21.
  51. Boucher M, Marquette GP, Varin J, et al. Fetomaternal hemorrhage during external cephalic version. Obstet Gynecol 2008; 112:79.
  52. Krause HG, Goh JT. Positive Kleihauer result following an ectopic pregnancy. Aust N Z J Obstet Gynaecol 1996; 36:324.
  53. Von Stein GA, Munsick RA, Stiver K, Ryder K. Fetomaternal hemorrhage in threatened abortion. Obstet Gynecol 1992; 79:383.
  54. Wylie BJ, D'Alton ME. Fetomaternal hemorrhage. Obstet Gynecol 2010; 115:1039.
  55. Standards for Blood Banks and Transfusion Services, Silva M (Ed), Amercian Association of Blood Banks, Bethesda, MD 2006.
  56. de Almeida V, Bowman JM. Massive fetomaternal hemorrhage: Manitoba experience. Obstet Gynecol 1994; 83:323.
  57. Sebring ES, Polesky HF. Fetomaternal hemorrhage: incidence, risk factors, time of occurrence, and clinical effects. Transfusion 1990; 30:344.
  58. Rubod C, Deruelle P, Le Goueff F, et al. Long-term prognosis for infants after massive fetomaternal hemorrhage. Obstet Gynecol 2007; 110:256.
  59. Stedman CM, Baudin JC, White CA, Cooper ES. Use of the erythrocyte rosette test to screen for excessive fetomaternal hemorrhage in Rh-negative women. Am J Obstet Gynecol 1986; 154:1363.
  60. Kumpel BM. Analysis of factors affecting quantification of fetomaternal hemorrhage by flow cytometry. Transfusion 2000; 40:1376.
  61. Ramsey G, College of American Pathologists Transfusion Medicine Resource Committee. Inaccurate doses of R immune globulin after rh-incompatible fetomaternal hemorrhage: survey of laboratory practice. Arch Pathol Lab Med 2009; 133:465.
  62. Standards for Blood Banks and Transfusion Services, 25th ed, American Association of Blood Banks, Bethesda, MD 2008.
  63. Lafferty J, Raby A, Keeney M, et al. Inaccurate doses of Rh immune globulin after Rh-incompatible fetomaternal hemorrhage-survey of laboratory practice. Arch Pathol Lab Med 2009; 133:1910.
  64. Larsen R, Berkowicz A, Lousen T, et al. Massive fetomaternal hemorrhage: clearance of fetal red blood cells after intravenous anti-D prophylaxis monitored by flow cytometry. Transfusion 2008; 48:1707.
  65. Samson D, Mollison PL. Effect on primary Rh immunization of delayed administration of anti-Rh. Immunology 1975; 28:349.
  66. Sandler SG, Gottschall JL. Postpartum Rh immunoprophylaxis. Obstet Gynecol 2012; 120:1428.
  67. Qureshi H, Massey E, Kirwan D, et al. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfus Med 2014; 24:8.
  68. Avent ND, Reid ME. The Rh blood group system: a review. Blood 2000; 95:375.
  69. Sandler SG, Flegel WA, Westhoff CM, et al. It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group. Transfusion 2015; 55:680.
  70. Sandler SG, Queenan JT. A Guide to Terminology for Rh Immunoprophylaxis. Obstet Gynecol 2017; 130:633.
Topic Outline